ACADIA Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Catherine Owen Adams

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2yrs
Durée moyenne du mandat des membres du conseil d'administration	9yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Catherine Owen Adams (54 yo)

less than a year

Titularisation

Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Mark Schneyer	Executive VP & CFO	3.2yrs	US$2.59m	0.032% $ 872.4k
Brendan Teehan	Executive VP	3yrs	US$2.62m	0.037% $ 1.0m
Stephen Davis	Consultant	less than a year	US$7.59m	0.11% $ 3.1m
Catherine Owen Adams	CEO & Director	less than a year	pas de données	pas de données
James Kihara	VP, Chief Accounting Officer & Corporate Controller	4.3yrs	pas de données	0.012% $ 325.2k
Elizabeth Thompson	Executive VP and Head of Research & Development	less than a year	pas de données	pas de données
Benir Ruano	Senior Vice President of Technical Development	2yrs	pas de données	pas de données
Albert Kildani	Senior Vice President of Investor Relations & Corporate Communications	1.2yrs	pas de données	pas de données
Jennifer Rhodes	Executive VP	less than a year	pas de données	pas de données
Holly Valdiviez	Senior VP & Head of Sales	2.8yrs	pas de données	pas de données
Rob Ackles	Senior VP & Chief People Officer	2.8yrs	pas de données	pas de données
Bob Mischler	Senior Vice President of New Product Planning & Strategy	no data	pas de données	pas de données

2.0yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0A4W est considérée comme expérimentée (ancienneté moyenne 2 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Catherine Owen Adams	CEO & Director	less than a year	pas de données	pas de données
Laura Brege	Independent Director	16.5yrs	US$392.75k	0.012% $ 329.9k
Julian Baker	Independent Director	8.9yrs	US$377.75k	0.062% $ 1.7m
Paul Anderson	Member of the Scientific and Clinical Advisory Board	no data	pas de données	pas de données
Edmund Harrigan	Independent Director	9yrs	US$387.75k	0.015% $ 420.0k
Daniel Soland	Independent Director	9.7yrs	US$387.75k	0.021% $ 567.4k
Arvid Carlsson	Member of the Scientific and Clinical Advisory Board	no data	pas de données	pas de données
Carol Tamminga	Member of the Scientific and Clinical Advisory Board	no data	pas de données	pas de données
Herbert Meltzer	Member of the Scientific and Clinical Advisory Board	no data	pas de données	pas de données
James Daly	Independent Director	8.8yrs	US$387.75k	0.015% $ 403.7k
Stephen Biggar	Independent Chairman of the Board	11.8yrs	US$432.75k	0.062% $ 1.7m
Elizabeth Garofalo	Independent Director	4.2yrs	US$377.75k	0.014% $ 368.5k

9.0yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0A4W sont considérés comme expérimentés (ancienneté moyenne 9 ans).

ACADIA Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

ACADIA Pharmaceuticals Inc., Annual General Meeting, May 29, 2024

ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals Inc. Announces Executive Changes

Acadia Pharmaceuticals Inc. Announces Management Changes

Doug Williamson to Leave ACADIA Pharmaceuticals Inc. as Executive Vice President, Head of Research and Development

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: US$0.20 (vs US$0.40 loss in 3Q 2023)

ACADIA Pharmaceuticals Inc. Revises Earnings Guidance for the Year 2024

ACADIA Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.20 (vs US$0.007 in 2Q 2023)

ACADIA Pharmaceuticals Inc. Revises Earnings Guidance for the Full Year of 2024

ACADIA Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024

Acadia Pharmaceuticals Inc. Announces the Journal Med Published Results from Two Open-Label Extension Studies, LILAC-1 and LILAC-2

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.10 (vs US$0.27 loss in 1Q 2023)

ACADIA Pharmaceuticals Inc., Annual General Meeting, May 29, 2024

ACADIA Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting

ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

ACADIA Pharmaceuticals Inc. Provides Sales Guidance for the Full Year 2024

Full year 2023 earnings released: US$374 loss per share (vs US$1.34 loss in FY 2022)

ACADIA Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 27, 2024

Acadia Pharmaceuticals Inc. Announces Executive Changes

Acadia Pharmaceuticals Inc. Announces Management Changes

Acadia Pharmaceuticals Inc. Initiates Pivotal Phase 3 Study of Carbetocin (Acp-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

Acadia Pharmaceuticals Inc. Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis

Acadia Pharmaceuticals Inc. Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis

Doug Williamson to Leave ACADIA Pharmaceuticals Inc. as Executive Vice President, Head of Research and Development

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.17 loss in 3Q 2022)

ACADIA Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 02, 2023

Insufficient new directors

Acadia Pharmaceuticals Inc. Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals, Inc and Encourages Long-Term Acad Investors to Contact the Firm

Second quarter 2023 earnings released: EPS: US$0.007 (vs US$0.21 loss in 2Q 2022)

Acadia Pharmaceuticals Inc. Appoints Kevin R. Oliver as Senior Vice President, Chief Business Officer and Member of Executive Management Committee

ACADIA Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Second Quarter and Third Quarter of 2023

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (Intranasal Carbetocin) for Prader-Willi Syndrome

Nature Medicine Publishes Results from Pivotal Phase 3 Largender Study Evaluating Daybue (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.70 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Full year 2022 earnings released: US$1.34 loss per share (vs US$1.05 loss in FY 2021)

ACADIA Pharmaceuticals Inc. to Report Q4, 2022 Results on Feb 27, 2023

ACADIA Pharmaceuticals Inc. Announces Executive Changes

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

Acadia Pharmaceuticals Inc. Provides Sales Guidance for the Full Year of 2022

Acadia Pharmaceuticals Inc. Announces Retirement of Srdjan (Serge) Stankovic as President

ACADIA Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 02, 2022

Acadia Pharmaceuticals Inc Appoints Adora Ndu to Its Board of Directors

ACADIA Pharmaceuticals Inc. Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

No longer forecast to breakeven

ACADIA Pharmaceuticals Inc. Provides Sales Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2021)

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

ACADIA Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 08, 2022

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.41 loss in 1Q 2021)

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for Nuplazid

Insufficient new directors

ACADIA Pharmaceuticals Inc., Annual General Meeting, Jun 07, 2022

ACADIA Pharmaceuticals Inc. to Report Q1, 2022 Results on May 04, 2022

Acadia Pharmaceuticals Inc. Announces Top-Line Results from Phase 2 Study Evaluating Acp-044 for the Treatment of Acute Postoperative Pain

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Acadia Pharmaceuticals Inc. Provides Sales Guidance for the Year 2022

Acadia Pharmaceuticals Inc. Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis